PD-L1 expression in human cancers and its association with clinical outcomes

• Published in: OncoTargets and therapy Vol. 9; pp. 5023 - 5039
• Main Authors: Yu, Jinming, Wang, Xin, Teng, Feifei, Kong, Li
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2016; Dove Medical Press
• Subjects: Antigens; Apoptosis; Binding sites; Bladder; Bladder cancer; Breast cancer; Cancer immunotherapy; Cell growth; Clinical outcomes; Colorectal cancer; Cytokines; Dendritic cells; Esophageal cancer; Immune checkpoint; Kidney cancer; Ligands; Liver cancer; Lung cancer; Lymphocytes; Lymphoma; Medical prognosis; Melanoma; Ovarian cancer; Pancreatic cancer; PD-L1 protein; Renal cell carcinoma; Review; Signal transduction; Skin cancer; T cell receptors; Tumors; PD-L1; checkpoint blockade; prognostic value; clinical outcome; immunotherapy

PD-L1 is an immunoinhibitory molecule that suppresses the activation of T cells, leading to the progression of tumors. Overexpression of PD-L1 in cancers such as gastric cancer, hepatocellular carcinoma, renal cell carcinoma, esophageal cancer, pancreatic cancer, ovarian cancer, and bladder cancer i...